Urolithin A (Mitopure)

Urolithin A (Mitopure) is not a traditional food but a postbiotic metabolite naturally produced by gut microbiota (primarily Gordonibacter and Ellagibacter species) through fermentation of ellagitannins and ellagic acid found in pomegranates, walnuts, raspberries, and strawberries. As a bioactive compound, it has negligible macronutrient content (no significant protein, fat, carbohydrate, or fiber contribution). Key bioactive compound: Urolithin A (6H-dibenzo[b,d]pyran-6-one derivative), typically standardized at 500 mg per dose in commercial Mitopure formulations. Bioavailability notes: Only approximately 40% of the population possesses the gut microbiome capable of endogenously converting ellagitannins to Urolithin A, making direct supplementation significant. Oral bioavailability is moderate; Urolithin A undergoes phase II metabolism forming glucuronide and sulfate conjugates in the liver and intestinal wall. Peak plasma concentration (Cmax) is reached approximately 6–8 hours post-ingestion. Plasma half-life is approximately 17–25 hours, supporting once-daily dosing. The compound is lipophilic (molecular weight: 228.2 g/mol), and absorption may be enhanced when taken with a fat-containing meal. No vitamins or minerals are present in meaningful amounts. The primary mechanism of action involves selective mitophagy induction via PINK1/Parkin pathway activation, clearing dysfunctional mitochondria and stimulating biogenesis. Clinical doses studied range from 250 mg to 1000 mg/day, with 500 mg being the most commonly researched effective dose. Mitopure formulations may include additional carrier ingredients such as medium-chain triglycerides (MCTs) or pomegranate fruit extract providing trace ellagic acid (~50–100 mg) as a complementary polyphenol. Urolithin A also activates AMPK and sirtuin (SIRT1/SIRT3) signaling pathways, upregulates NAD+ metabolism, and has demonstrated reduction in circulating C-reactive protein (CRP) and pro-inflammatory cytokines (IL-6, TNF-α) in clinical trials.